ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
73 announcements with these filters
Religare Enterprises Limited has allotted 35,00,000 equity shares following the conversion of an equivalent number of warrants. This capital structure change increases the total paid-up share capital.
Religare Enterprises Limited allotted 35,00,000 equity shares to Puran Associates Private Limited (Promoter Group). This follows the conversion of warrants at a price of Rs. 235 per share.
Religare Enterprises' subsidiary, MIC, has surrendered its Insurance Web Aggregator license to the IRDAI. The company confirms no material impact as the unit is not currently operating.
Religare Enterprises announced that SEBI has disposed of the Interim Order and Show Cause Notice dated June 19, 2024, without issuing any directions against the company.
Religare Enterprises announced the resignation of Anuj Jain, Company Secretary and Compliance Officer, effective from the close of business hours on July 31, 2026.
Religare Enterprises Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI requirements.
Religare Enterprises subscribed to a rights issue by its subsidiary, Care Health Insurance, for Rs. 119.69 Crore. The investment supports the subsidiary's expansion and solvency requirements.
Religare Enterprises approved the continuation of Mr. Rajender Mohan Malla as Non-Executive Chairperson. His term is extended for the July-September 2026 quarter on a rotational basis.
Religare Enterprises received 'no objection' for its demerger scheme. The restructuring, subject to statutory approvals, aims to separate its businesses.
ICRA has reaffirmed the [ICRA]BBB- (Stable) rating for Religare Housing's bank lines. The rating applies to a rated amount of ₹400 Crore.
Religare Enterprises appointed Pavan Kumar Gupta as MD and CEO of its subsidiary RHDFCL. The appointment is effective from July 1, 2026.
Religare Enterprises Limited allotted 83,43,263 equity shares following the conversion of warrants. This increases the company's total paid-up share capital to 34,12,33,742 shares.
Religare Enterprises allotted 83,43,263 equity shares following warrant conversions, receiving ₹147.05 Crore in funds. This conversion increases the company's total paid-up share capital.
Religare Enterprises allotted 83,43,263 equity shares following warrant conversions, totaling ₹196.07 Crore. The allotment increases paid-up capital and concludes the 18-month warrant exercise period.
Religare Enterprises clarified an inadvertent 'audited' selection in its Q4FY26 XBRL financial results filing. The company is taking steps to submit corrected forms to the exchange.
Religare Enterprises reported FY26 consolidated total income of ₹8,493cr and PAT of ₹73.16cr. Management is restructuring via demerger into two listed entities: Health Insurance and Financial Services.
Religare Enterprises designated Group General Counsel Babu Rao Priya as Key Managerial Personnel. The move strengthens corporate governance and formalizes senior leadership responsibilities.
Religare Enterprises Limited filed its monitoring report for the ₹1,500.00 Crore warrant issue proceeds. The agency confirmed utilization aligns with specified objects without deviations.
Religare Enterprises Ltd reported revenue from operations of ₹2,467 Cr (+20.8% YoY) and net profit of ₹95.7 Cr (-36.5% YoY) for Q4 FY26.
Religare Enterprises reported FY26 consolidated revenue of ₹8,493.84 Crore, driven by 24% growth in health insurance. Strategic leadership appointments and a ₹1,500 Crore capital raise support growth.
Religare Enterprises approved closing its subsidiary, MIC Insurance Web Aggregator, by surrendering its license. The shutdown has no material impact on the company's consolidated financials.
Religare Enterprises updated its Key Managerial Personnel contact details for determining disclosure materiality. This administrative filing ensures regulatory compliance under SEBI LODR Regulations.
Religare Enterprises designated Mr. Babu Rao Priya as Key Managerial Personnel. He continues as Group General Counsel and Group Chief Compliance Officer until November 2030.
Religare Enterprises approved audited standalone and consolidated financial results for fiscal year 2026. The company reported consolidated net profit of ₹73.16 Crore.
Religare Enterprises appointed Mr. Srinivasan Karthik as CEO and Managing Director of its subsidiary Religare Finvest. The leadership change takes effect from May 05, 2026.
Religare's subsidiary, Care Health Insurance, received a rectification order reducing its tax liability to ₹45.16 Crore. The company continues to appeal the original assessment additions.
Religare Enterprises Limited has scheduled a Board meeting on May 12, 2026, to approve audited standalone and consolidated financial results for the year ended March 31, 2026. The company also confirmed its trading window remains closed until May 14, 2026.
Religare Enterprises Limited shareholders approved shifting the company's Registered Office from Delhi to Haryana. This involves an amendment to Clause II of the Memorandum of Association, subject to regulatory approvals. The move centralizes administrative operations in Haryana.
Religare Enterprises Limited announced the voting results of its EGM held on May 05, 2026. Shareholders approved shifting the registered office to Haryana and the appointment of Mr. Arjun Lamba as Whole Time Director with 98.48% and 95.53% majority respectively. The resolutions were passed as special resolutions via remote e-voting and poll.
Religare Enterprises Limited conducted an Extra Ordinary General Meeting on May 05, 2026, via video conferencing. Shareholders considered special resolutions regarding shifting the registered office from Delhi to Haryana and appointing Mr. Arjun Lamba as Whole Time Director. Voting results will be submitted separately after the scrutinizer's report.